Retrospective Chart Review of Subcutaneous IgG Use in Infants
Recruiting in Palo Alto (17 mi)
+4 other locations
MB
Overseen byMelvin Berger, MD, PhD
Age: < 18
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: CSL Behring
No Placebo Group
Trial Summary
What is the purpose of this trial?
This study is a retrospective chart review of the use of subcutaneous IgG (SCIG) in infants less than two years old.
Research Team
MB
Melvin Berger, MD, PhD
Principal Investigator
CSL Behring
Eligibility Criteria
Inclusion Criteria
Infants who received more than one dose of IgG by the subcutaneous route before the age of two years.
Consent of parent/guardian if required by institution/IRB.
Treatment Details
Interventions
- Subcutaneous IgG (SCIG) (Immunoglobulin Replacement Therapy)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: SCIGExperimental Treatment1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
CSL Behring
Lead Sponsor
Trials
204
Recruited
1,207,000+
Dr. Paul McKenzie
CSL Behring
Chief Executive Officer since 2023
PhD in Chemical Engineering from Carnegie Mellon University, B.S. in Chemical Engineering from the University of Pennsylvania
Dr. Bill Mezzanotte
CSL Behring
Chief Medical Officer since 2021
MD from Duke University